RYTM

In the past six months (April to October 2026), Rhythm Pharmaceuticals' stock has been influenced by several events. Health Canada approved IMCIVREE for acquired hypothalamic obesity on September 22, 2026, leading to a positive stock movement. The CEO sold 50,000 shares on September 14, 2026, and the CFO sold 62,774 shares on September 1, 2026, both under preset plans. Japan's MHLW approved IMCIVREE for acquired hypothalamic obesity on August 24, 2026. On August 4, 2026, the company reported strong Q2 2026 financial results, highlighting a successful U.S. launch of IMCIVREE for acquired hypothalamic obesity and positive Phase 2 results for setmelanotide in Prader-Willi syndrome and RM-718 in acquired HO patients. The U.S. FDA approved IMCIVREE for acquired hypothalamic obesity on March 19, 2026, which had a lasting impact on investor sentiment. Over the past six months, RYTM stock has fluctuated, with a significant daily increase of +12.6% on March 31, 2026, but a more recent downward trend, showing a 1-month change of -13.91% and a 3-month change of -22.70% as of October 7, 2026. From the start of 2026 to October 8, 2026, RYTM shares decreased by 17.4%.